Page last updated: 2024-10-24

tumor necrosis factor receptor binding

Definition

Target type: molecularfunction

Binding to a tumor necrosis factor receptor. [GOC:ai]

Tumor necrosis factor receptor (TNFR) binding is a crucial process in the regulation of immune responses, inflammation, and cell survival. TNFRs are transmembrane proteins that belong to the TNF receptor superfamily. They play a central role in mediating the biological effects of TNF-α, a pleiotropic cytokine involved in various cellular processes.

The interaction between TNF-α and TNFRs initiates a complex signaling cascade, ultimately leading to the activation of downstream transcription factors and signaling pathways. This intricate interplay between TNF-α and TNFRs is essential for maintaining cellular homeostasis and regulating inflammatory responses.

TNF-α binds to its receptor TNFR1 (also known as p55), which is expressed on various cell types, including immune cells, endothelial cells, and fibroblasts. This interaction triggers the recruitment of adaptor proteins, such as TRADD and TRAF2, to the cytoplasmic domain of TNFR1. The assembly of these adaptor proteins leads to the activation of downstream signaling pathways, including the NF-κB pathway and the MAPK pathway.

The NF-κB pathway is a crucial regulator of gene expression, promoting the production of pro-inflammatory cytokines, chemokines, and cell adhesion molecules. Activation of the NF-κB pathway contributes to the inflammatory response by recruiting immune cells to the site of inflammation and promoting the expression of genes involved in immune defense.

The MAPK pathway is another important signaling pathway activated by TNFR1 engagement. MAPKs, such as ERK, JNK, and p38, are involved in regulating cell growth, differentiation, and apoptosis. Activation of the MAPK pathway by TNFR1 can promote cell survival or induce apoptosis, depending on the cellular context and the specific MAPKs involved.

TNF-α can also bind to TNFR2 (also known as p75). TNFR2 is primarily expressed on immune cells and plays a role in regulating apoptosis and immune cell differentiation. However, unlike TNFR1, TNFR2 does not directly activate the NF-κB pathway. Instead, TNFR2 signaling primarily involves the activation of the MAPK pathway and the induction of apoptosis.

In addition to its role in immune responses, TNFR signaling has been implicated in various pathological conditions, including cancer, autoimmune diseases, and neurodegenerative diseases. Dysregulation of TNFR signaling can contribute to the development and progression of these diseases. Therefore, targeting TNFR signaling pathways has emerged as a promising therapeutic strategy for treating these conditions.

In summary, TNFR binding is a complex molecular function that plays a critical role in regulating immune responses, inflammation, and cell survival. The interaction between TNF-α and its receptors triggers a cascade of signaling events, ultimately leading to the activation of various downstream pathways involved in cellular function and response to stress.'
"

Proteins (5)

ProteinDefinitionTaxonomy
Caspase-8A caspase-8 that is encoded in the genome of human. [PRO:DNx]Homo sapiens (human)
Heat shock protein 75 kDa, mitochondrialA heat shock protein 75 kDa, mitochondrial that is encoded in the genome of human. [PRO:DAN]Homo sapiens (human)
Signal transducer and activator of transcription 1-alpha/betaA signal transducer and activator of transcription 1 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P42224]Homo sapiens (human)
Tumor necrosis factorA tumor necrosis factor that is encoded in the genome of human. [PRO:DNx]Homo sapiens (human)
Tumor necrosis factor ligand superfamily member 11A tumor necrosis factor ligand superfamily member 11 that is encoded in the genome of human. [PRO:WCB, UniProtKB:O14788]Homo sapiens (human)

Compounds (51)

CompoundDefinitionClassesRoles
mesalaminemesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.

Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
amino acid;
aromatic amine;
monocarboxylic acid;
monohydroxybenzoic acid;
phenols
non-steroidal anti-inflammatory drug
way 151693
pentoxifyllineoxopurine
3,3',4,5'-tetrahydroxystilbenestilbenoid
4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone: Inhibitor of phosphodiesterases.methoxybenzenes
roliprampyrrolidin-2-onesantidepressant;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
sulfasalazinesulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.

Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
adenosine diphosphateAdenosine Diphosphate: Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position.adenosine 5'-phosphate;
purine ribonucleoside 5'-diphosphate
fundamental metabolite;
human metabolite
suramin sodiumsuramin sodium : An organic sodium salt that is the hexasodium salt of suramin. It is an FDA approved drug for African sleeping sickness and river blindness.organic sodium saltangiogenesis inhibitor;
antinematodal drug;
antineoplastic agent;
apoptosis inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
GABA antagonist;
GABA-gated chloride channel antagonist;
purinergic receptor P2 antagonist;
ryanodine receptor agonist;
trypanocidal drug
isoquinoline-1,3,4-trioneisoquinoline-1,3,4-trione: structure in first source
n-methylisatinN-methylisatin: structure given in first source
epigallocatechin gallate(-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin.

epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis)
flavans;
gallate ester;
polyphenol
antineoplastic agent;
antioxidant;
apoptosis inducer;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent;
plant metabolite
bergeninbergenin: RN refers to (2R-(2alpha,3beta,4alpha,4aalpha,10bbeta))-isomer; structuretrihydroxybenzoic acidmetabolite
2,2'-((3,3'-dimethoxy(1,1'-biphenyl)-4,4'-diyl)diimino)bis-benzoic acid2,2'-((3,3'-dimethoxy(1,1'-biphenyl)-4,4'-diyl)diimino)bis-benzoic acid: structure given in first source
stictic acidstictic acid: antioxidant from lichen, Usnea articulata; structure in first sourcearomatic ether
marimastatmarimastat : A secondary carboxamide resulting from the foraml condensation of the carboxy group of (2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoic acid with the alpha-amino group of N,3-dimethyl-L-valinamide.

marimastat: a matrix metalloproteinase inhibitor active in patients with advanced carcinoma of the pancreas, prostate, or ovary
hydroxamic acid;
secondary carboxamide
antineoplastic agent;
matrix metalloproteinase inhibitor
pralnacasanpralnacasan: NSAID, ICE inhibitor & metastasis inhibitor; RN & structure in first source
birb 796aromatic ether;
morpholines;
naphthalenes;
pyrazoles;
ureas
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
immunomodulator
nsc 74859NSC 74859: inhibits Stat3 binding activity; structure in first source

S3I-201 : An amidobenzoic acid obtained by formal condensation of the carboxy group of [(4-methylbenzene-1-sulfonyl)oxy]acetic acid with the amino group of 4-amino-2-hydroxybenzoic acid.
amidobenzoic acid;
monohydroxybenzoic acid;
tosylate ester
STAT3 inhibitor
1,3(2h,4h)-isoquinolinedione1,3(2H,4H)-isoquinolinedione: structure in first source
ganoderic acid atriterpenoid
ganoderiol fganoderiol F: a ganoderma triterpene from Ganoderma amboinense; structure in first sourcetriterpenoid
1-(phenylmethyl)benzimidazolebenzimidazoles
acetyl-aspartyl-glutamyl-valyl-aspartalAc-Asp-Glu-Val-Asp-H : A tetrapeptide consisting of two L-aspartic acid residues, an L-glutamyl residue and an L-valine residue with an acetyl group at the N-terminal and with the C-terminal carboxy group reduced to an aldehyde. It is an inhibitor of caspase-3/7.

acetyl-aspartyl-glutamyl-valyl-aspartal: a capase inhibitor
tetrapeptideprotease inhibitor
1,6-dimethyl-3-(2-pyridinyl)pyrimido[5,4-e][1,2,4]triazine-5,7-dionepyrimidotriazine
1,6-dimethyl-3-propylpyrimido[5,4-e][1,2,4]triazine-5,7-dionepyrimidotriazine
5-Nitroisatinindolesanticoronaviral agent
luteolin-7-glucosideluteolin 7-O-beta-D-glucoside : A glycosyloxyflavone that is luteolin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.

luteolin-7-glucoside: has both antiasthmatic and antineoplastic activities; has 3C protease inhibitory activity; isolated from Ligustrum lucidum
beta-D-glucoside;
glycosyloxyflavone;
monosaccharide derivative;
trihydroxyflavone
antioxidant;
plant metabolite
apigetrinapigenin 7-O-beta-D-glucoside : A glycosyloxyflavone that is apigenin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.

apigetrin: structure given in first source
beta-D-glucoside;
dihydroxyflavone;
glycosyloxyflavone;
monosaccharide derivative
antibacterial agent;
metabolite;
non-steroidal anti-inflammatory drug
geldanamycin1,4-benzoquinones;
ansamycin;
carbamate ester;
organic heterobicyclic compound
antimicrobial agent;
antineoplastic agent;
antiviral agent;
cysteine protease inhibitor;
Hsp90 inhibitor
n-acetyltyrosyl-valyl-alanyl-aspartyl aldehyde
benzyloxycarbonyl-phe-ala-fluormethylketonecathepsin B inhibitor : A cysteine protease inhibitor which inhibits cathepsin B (EC 3.4.22.1).
calycosin-7-o-beta-d-glucopyranosidecalycosin-7-O-beta-D-glucoside : A glycosyloxyisoflavone that is calycosin substituted by a beta-D-glucopyranosyl residue at position at 7 via a glycosidic linkage.

calycosin-7-O-beta-D-glucoside: from Radix Astragali
4'-methoxyisoflavones;
7-hydroxyisoflavones 7-O-beta-D-glucoside;
hydroxyisoflavone;
monosaccharide derivative
spd-304SPD-304: structure in first source
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone
nf 449
tanespimycinCP 127374: analog of herbimycin A1,4-benzoquinones;
ansamycin;
carbamate ester;
organic heterobicyclic compound;
secondary amino compound
antineoplastic agent;
apoptosis inducer;
Hsp90 inhibitor
9h-purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-n-(1-methylethyl)-9H-purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-N-(1-methylethyl)-: an epichaperome (purine-scaffold) inhibitor; structure in first source
5,15-diphenylporphine5,15-diphenylporphine: structure in first source
ec 144EC 144: structure in first source
guttiferone kguttiferone K: antiproliferative compound of Rheedia calcicola from the Madagascar rain forest; structure in first source
cnf 20242-aminopurines;
aromatic ether;
organochlorine compound;
pyridines
antineoplastic agent;
Hsp90 inhibitor
ganoderic acid fganoderic acid F: isolated from Ganoderma lucidum; structure in first sourcetriterpenoid
snx 2112SNX 2112: an orally available small molecule Hsp90 inhibitor; structure in first source
debio 0932CUDC 305: an Hsp90 inhibitor with antineoplastic activity; structure in first source
grassystatin agrassystatin A: isolated from a cyanobacterium, identified as Lyngbya cf.; structure in first source
ganoderic acid c2ganoderic acid C2: from the fruiting body of Ganoderma; structure in first sourcetriterpenoid
MK-8353MK-8353 : A member of the class of indazoles that is 1H-indazole substituted by a 6-(propan-2-yloxy)pyridin-3-yl group at position 3 and by a {[(3S)-3-(methylsulfanyl)-1-(2-{4-[4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]-3,6-dihydropyridin-1(2H)-yl}-2-oxoethyl)pyrrolidin-3-yl]carbonyl}amino group at position 5. It is a potent and selective inhibitor of ERK1 and ERK2 in vitro (IC50 values of 23.0 nM and 8.8 nM, respectively). The drug is being developed by Merck Sharp & Dohme and is currently in clinical development for the treatment of advanced/metastatic solid tumors.

MK-8353: ERK inhibitor used in oncology
aromatic ether;
dihydropyridine;
indazoles;
methyl sulfide;
N-alkylpyrrolidine;
pyridines;
pyrrolidinecarboxamide;
secondary carboxamide;
tertiary carboxamide;
triazoles
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
tas-116
ver 52296luminespib : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-(2,4-dihydroxy-5-isopropylphenyl)-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-3-carboxylic acid with the amino group of ethylamine.aromatic amide;
isoxazoles;
monocarboxylic acid amide;
morpholines;
resorcinols
angiogenesis inhibitor;
antineoplastic agent;
Hsp90 inhibitor
sta 9090ring assembly;
triazoles